{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:38:12Z","timestamp":1791934692120,"version":"4.3.4"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Melatonin is the \u201cclock factor\u201d generated from pineal gland dominating regular circadian rhythm in humans. Migraine is one of the most severe and debilitating primary headache disorders. Thus far, many diseases have been found to associate with melatonin, including the migraine. Therefore, melatonin's therapeutic potential for migraine is drawing attention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The aim of this study is to offer a systematic review of extant data of melatonin in migraine prophylaxis and to provide clinical implications and specific recommendations for future studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources and study methods<\/jats:title>\n                    <jats:p>A systematic research was conducted in September 2018 by using PubMed and Google Scholar databases to search for science literature published after 1988.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In all, 7 eligible articles were identified, including 4 randomized controlled studies and 3 observational studies. Due to high heterogeneities and limited number of studies, meta-analysis was not feasible, and only systematic review was performed. The results show that present evidence cannot claim melatonin's effectiveness according to the conflicting outcomes; however, the two negative outcomes of melatonin not different from placebo and melatonin inferior to amitriptyline are possible under-powering because of methodological, pharmacological, and therapeutic shortcomings. Observational studies also support melatonin's efficacy in migraine. As a result, melatonin is very likely to benefit migraine in prophylaxis and may have a similar effectiveness to other main preventive medications. Immediate-release melatonin 3\u200amg was established as effective, melatonin receptor agonist (Agomelatine) 25\u200amg and prolonged-release melatonin 4\u200amg were observed efficacious in observational studies. Melatonin displayed ineffective in the 2-month trial; thus, 3 months or more may be an enough duration for migraine therapy. Despite melatonin being generally safe, emerging literature is illustrating that a few severe adverse effects can be caused by melatonin, for example, liver injuries, reproductive system dysfunctions, and detrimental immunostimulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Melatonin is very likely to be a promising alternative for migraine prophylaxis. Current literature examining melatonin's efficacy in migraine prevention is growing, but still limited. Future studies of perfect design in methodology, pharmacology, and therapeutics are needed to achieve a deeper awareness of melatonin's role in migraine as well as more studies to explore the safety issues of melatonin medicine.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000014099","type":"journal-article","created":{"date-parts":[[2019,1,16]],"date-time":"2019-01-16T22:06:45Z","timestamp":1547676405000},"page":"e14099","source":"Crossref","is-referenced-by-count":59,"title":["Therapeutic role of melatonin in migraine prophylaxis"],"prefix":"10.1097","volume":"98","author":[{"given":"Rujin","family":"Long","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousheng","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shusheng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1021\/ja01543a060","article-title":"Isolation of melatonin, the pineal gland factor that lightens melanocytes1","volume":"80","author":"Lerner","year":"1958","journal-title":"J Am Chem Soc"},{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00441-002-0580-5","article-title":"The anatomy and innervation of the mammalian pineal gland","volume":"309","author":"M\u00f8ller","year":"2002","journal-title":"Cell Tissue Res"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1046\/j.1468-2982.1995.015002136.x","article-title":"Nocturnal melatonin excretion is decreased in patients with migraine without aura attacks associated with menses","volume":"15","author":"Brun","year":"1995","journal-title":"Cephalalgia"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"135","DOI":"10.5152\/eurasianjmed.2015.0267","article-title":"A review of melatonin, its receptors and drugs","volume":"48","author":"Emet","year":"2016","journal-title":"Eurasian J Med"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.drudis.2014.04.014","article-title":"Melatonin: functions and ligands","volume":"19","author":"Singh","year":"2014","journal-title":"Drug Discov Today"},{"key":"R6-20230914","first-page":"194","article-title":"Melatonin in aging and disease\u2014multiple consequences of reduced secretion, options and limits of treatment","volume":"3","author":"Hardeland","year":"2012","journal-title":"Aging Dis"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.pneurobio.2008.04.001","article-title":"Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways","volume":"85","author":"Pandi-Perumal","year":"2008","journal-title":"Prog Neurobiol"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1136\/jnnp.2009.192492","article-title":"Sociodemographic and comorbidity profiles of chronic migraine and episodic migraine sufferers","volume":"81","author":"Buse","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"(Suppl 1)","key":"R9-20230914","article-title":"Migraine pathophysiology: anatomy of the trigeminovascular pathway and associated neurological symptoms, CSD, sensitization and modulation of pain","volume":"154","author":"Noseda","year":"2013","journal-title":"Pain"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1749-6632.2000.tb05402.x","article-title":"Melatonin and its relation to the immune system and inflammation","volume":"917","author":"Reiter","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1006\/cbir.1996.0091","article-title":"Effect of melatonin on NF-kappa-B DNA-binding activity in the rat spleen","volume":"20","author":"Chuang","year":"1996","journal-title":"Cell Biol Int"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40122-016-0049-y","article-title":"Melatonin in chronic pain syndromes","volume":"5","author":"Danilov","year":"2016","journal-title":"Pain Ther"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1212\/WNL.49.3.650","article-title":"Dopamine and migraine","volume":"49","author":"Peroutka","year":"1997","journal-title":"Neurology"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1600-079X.1996.tb00260.x","article-title":"Melatonin reduces nitric oxide synthase activity in rat hypothalamus","volume":"20","author":"Bettahi","year":"1996","journal-title":"J Pineal Res"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1023\/A:1015187601628","article-title":"Melatonin-dopamine interactions: from basic neurochemistry to a clinical setting","volume":"21","author":"Zisapel","year":"2001","journal-title":"Cell Mol Neurobiol"},{"key":"R16-20230914","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1017\/S1092852900018757","article-title":"The link between glutamate and migraine","volume":"8","author":"Ramadan","year":"2003","journal-title":"CNS Spectr"},{"key":"R17-20230914","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1517\/13543784.15.4.367","article-title":"Potential therapeutic use of melatonin in migraine and other headache disorders","volume":"15","author":"Peres","year":"2006","journal-title":"Expert Opin Investig Drugs"},{"key":"R18-20230914","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/00023210-200620050-00001","article-title":"Role of melatonin in the pathophysiology of migraine: implications for treatment","volume":"20","author":"Vogler","year":"2006","journal-title":"CNS Drugs"},{"key":"R19-20230914","first-page":"304","article-title":"Melatonin agonists modulate 5-HT2A receptor-mediated neurotransmission: behavioral and biochemical studies in the rat","volume":"273","author":"Eison","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"R20-20230914","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0924-977X(00)00115-2","article-title":"Anti-depressant action of melatonin in chronic forced swimming-induced behavioral despair in mice, role of peripheral benzodiazepine receptor modulation","volume":"10","author":"Raghavendra","year":"2000","journal-title":"Eur Neuropsychopharmacol"},{"key":"R21-20230914","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0278-5846(03)00149-0","article-title":"Corticosterone attenuates the antidepressant-like effects elicited by melatonin in the forced swim test in both male and female rats","volume":"27","author":"Hill","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R22-20230914","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0304-3940(03)00306-9","article-title":"Melatonin exerts an antidepressant-like effect in the tail suspension test in mice: evidence for involvement of N-methyl-d-aspartate receptors and the l-arginine-nitric oxide pathway","volume":"343","author":"Mantovani","year":"2003","journal-title":"Neurosci Lett"},{"key":"R23-20230914","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1526-4610.2009.01547.x","article-title":"Urinary 6-sulphatoxymelatonin levels are depressed in chronic migraine and several comorbidities","volume":"50","author":"Masruha","year":"2010","journal-title":"Headache"},{"key":"R24-20230914","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10194-008-0047-5","article-title":"Low urinary 6-sulphatoxymelatonin concentrations in acute migraine","volume":"9","author":"Masruha","year":"2008","journal-title":"J Headache Pain"},{"key":"R25-20230914","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1600-079X.2011.00941.x","article-title":"Pain in neonatal intensive care: role of melatonin as an analgesic antioxidant","volume":"52","author":"Gitto","year":"2012","journal-title":"J Pineal Res"},{"key":"R26-20230914","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1111\/jpi.12134","article-title":"Melatonin as a potential therapy for sepsis: a phase I dose escalation study and an ex vivo whole blood model under conditions of sepsis","volume":"56","author":"Galley","year":"2014","journal-title":"J Pineal Res"},{"key":"R27-20230914","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00008390-199111000-00003","article-title":"Melatonin therapy of advanced human malignant melanoma","volume":"1","author":"Gonzalez","year":"1991","journal-title":"Melanoma Res"},{"key":"R28-20230914","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1212\/WNL.0b013e3181f9618c","article-title":"Prophylaxis of migraine with melatonin: a randomized controlled trial","volume":"75","author":"Alstadhaug","year":"2010","journal-title":"Neurology"},{"key":"R29-20230914","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1136\/jnnp-2016-313458","article-title":"Randomised clinical trial comparing melatonin 3\u200amg, amitriptyline 25\u200amg and placebo for migraine prevention","volume":"87","author":"Gon\u00e7alves","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R30-20230914","first-page":"385","article-title":"Use of melatonin versus valproic acid in prophylaxis of migraine patients: a double-blind randomized clinical trial","volume":"35","author":"Ebrahimi-Monfared","year":"2017","journal-title":"Restor Neurol Neurosci"},{"key":"R31-20230914","first-page":"47","article-title":"A randomized clinical trial comparing the efficacy of melatonin and amitriptyline in migraine prophylaxis of children","volume":"12","author":"Fallah","year":"2018","journal-title":"Iran J Child Neurol"},{"key":"R32-20230914","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1212\/01.WNL.0000134653.35587.24","article-title":"Melatonin, 3\u200amg, is effective for migraine prevention","volume":"63","author":"Peres","year":"2004","journal-title":"Neurology"},{"key":"R33-20230914","first-page":"33","article-title":"Melatonin 4\u200amg as prophylactic therapy for primary headaches: a pilot study","volume":"31","author":"Bougea","year":"2016","journal-title":"Funct Neurol"},{"key":"R34-20230914","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1177\/2045125315584869","article-title":"Agomelatine and migraine management: a successfully treated case series","volume":"5","author":"Plasencia-Garc\u00eda","year":"2015","journal-title":"Ther Adv Psychopharmacol"},{"key":"R35-20230914","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/pharmaceutics8010002","article-title":"Dissolution of intact, divided and crushed circadin tablets: prolonged vs. immediate release of melatonin","volume":"8","author":"Chua","year":"2016","journal-title":"Pharmaceutics"},{"key":"R36-20230914","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1365-2869.2007.00613.x","article-title":"Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects","volume":"16","author":"Lemoine","year":"2007","journal-title":"J Sleep Res"},{"key":"R37-20230914","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1185\/030079907X233098","article-title":"Efficacy of prolonged release melatonin in insomnia patients aged 55\u201380 years: quality of sleep and next-day alertness outcomes","volume":"23","author":"Wade","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"R38-20230914","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1517\/14656566.2012.667076","article-title":"Prolonged-release formulation of melatonin (Circadin) for the treatment of insomnia","volume":"13","author":"Lemoine","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"R39-20230914","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.neuropharm.2014.12.004","article-title":"Tasimelteon: a selective and unique receptor binding profile","volume":"91","author":"Lavedan","year":"2015","journal-title":"Neuropharmacology"},{"key":"R40-20230914","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1503\/jpn.130009","article-title":"Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: a novel target in psychopharmacology","volume":"39","author":"Comai","year":"2014","journal-title":"J Psychiatry Neurosci"},{"key":"R41-20230914","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2165\/00023210-200519120-00007","article-title":"Ramelteon","volume":"19","author":"McGechan","year":"2005","journal-title":"CNS Drugs"},{"key":"R42-20230914","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1055\/s-0033-1353156","article-title":"Agomelatine and hepatotoxicity: implications of cumulated data derived from spontaneous reports of adverse drug reactions","volume":"46","author":"Gahr","year":"2013","journal-title":"Pharmacopsychiatry"},{"key":"R45-20230914","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40303-015-0011-7","article-title":"Systematic review of agomelatine-induced liver injury","volume":"3","author":"Freiesleben","year":"2015","journal-title":"J Mol Psychiatry"},{"key":"R48-20230914","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1017\/neu.2014.28","article-title":"Agomelatine-induced liver injury in a patient with choledocholithiasis. Acta Neuropsychiatr","volume":"27","author":"Eder","year":"2015","journal-title":"Acta Neuropsychiatr"},{"key":"R49-20230914","first-page":"87","article-title":"Pineal factors in the control of testicular function","volume":"2","author":"Kinson","year":"1976","journal-title":"Adv Sex Horm Res"},{"key":"R50-20230914","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/j.1939-4640.2002.tb02281.x","article-title":"Melatonin administration alters semen quality in healthy men","volume":"23","author":"Luboshitzky","year":"2002","journal-title":"J Androl"},{"key":"R51-20230914","doi-asserted-by":"crossref","first-page":"467","DOI":"10.4088\/JCP.07m03834","article-title":"Safety and subjective sleep effects of ramelteon administration in adults and older adults with chronic primary insomnia: a 1-year, open-label study","volume":"70","author":"Richardson","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"R52-20230914","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejphar.2015.11.054","article-title":"Studies on the reproductive effects of chronic treatment with agomelatine in the rat","volume":"770","author":"Canpolat","year":"2016","journal-title":"Eur J Pharmacol"},{"key":"R53-20230914","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1365-2125.2007.02911.x","article-title":"Inflammatory status and kynurenine metabolism in rheumatoid arthritis treated with melatonin","volume":"64","author":"Forrest","year":"2007","journal-title":"Br J Clin Pharmacol"},{"key":"R54-20230914","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/MCG.0b013e31829174f0","article-title":"Autoimmune hepatitis in association with ramelteon","volume":"47","author":"Fourman","year":"2013","journal-title":"J Clin Gastroenterol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201901180-00045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T00:29:29Z","timestamp":1720916969000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201901180-00045"}},"subtitle":["A systematic review"],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000014099","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}